Multiple evanescent white dot syndrome following influenza immunization - A multimodal imaging study

Caleb C. Ng\textsuperscript{a, b, *}, J. Michael Jumper\textsuperscript{a, b}, Emmett T. Cunningham Jr.\textsuperscript{a, b, c, d}

\textsuperscript{a} The Department of Ophthalmology, California Pacific Medical Center, San Francisco, CA, USA
\textsuperscript{b} West Coast Retina Medical Group, San Francisco, CA, USA
\textsuperscript{c} The Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA
\textsuperscript{d} The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, CA, USA

\begin{abstract}
Purpose: To describe the multimodal imaging (MMI) findings and clinical course of a case of Multiple Evanescent White Dot Syndrome (MEWDS) following immunization with inactivated intra-dermal influenza virus, and to explore whether similarities exist with other, previously reported cases.

Observations: A 34-year-old Caucasian man presented with unilateral onset of para-central scotomata, photopsias, and dyschromatopsia two weeks after administration of an influenza vaccine. Clinical examination and MMI were indicative of MEWDS. The patient’s MMI abnormalities and symptoms resolved spontaneously after four weeks.

Conclusion and importance: This is the first reported case of MMI of post-influenza vaccination-associated MEWDS. Comparison with eight previously reported cases of MEWDS following various immunizations revealed that subjects tended to be healthy, young to middle age women with a median time to onset of two weeks. Vision tended to recover spontaneously over one to three months.
\end{abstract}

1. Introduction

There is growing awareness regarding an association between vaccinations and uveitis.\textsuperscript{1-7} While the vast majority of cases have been associated with anterior uveitis, selected reports of posterior uveitis following immunization have also appeared. To the best of our knowledge, eight cases of vaccination-associated multiple evanescent white dot syndrome (MEWDS) have been reported previously.\textsuperscript{1,3-11} We add here the description of a ninth case of MEWDS following immunization with inactivated intra-dermal influenza virus, and include for the first time full multimodal imaging (MMI) of such a case. Characteristics and outcomes of all nine cases are summarized and compared.

2. Case report

A 34-year-old Caucasian man with a prior myopic-photorefractive keratectomy presented with the chief complaints of para-central scotomata, grey haze, and central photopsias affecting his right eye for two weeks. Past ophthalmic, medical and surgical histories were otherwise unremarkable. Snellen visual acuity was 20/20+2 on the right and 20/13-1 on the left. Intraocular pressure was 18 mmHg on the right and 14 mmHg on the left. Pupils, extraocular motility, and confrontation visual fields were unremarkable. Anterior segment examination was normal. Examination of the right-sided posterior segment was notable for mild foveal granularity and small, grey, outer-retinal lesions centered around the optic nerve with extension to the mid-periphery (Fig. 1A). The posterior segment of the left eye was unremarkable. At the locations of the grey retinal lesions, spectral domain-optical coherence tomography (SD-OCT) showed focal areas photoreceptor disruption (Fig. 1B); fundus autofluorescence revealed hyper-autofluorescence (Fig. 1E); indocyanine green angiography showed late hypofluorescence (Fig. 1D), and fluorescein angiography revealed multiple punctate areas of staining organized in a well-recognized wreath-like pattern (Fig. 1C). Collectively, these clinical and MMI findings lead to the diagnosis of MEWDS.

Upon further inquiry, our patient denied any preceding viral symptoms, but did reveal that he received Flucelvax Quadrivalent® influenza vaccine (Seqirus, Holly Springs, North Carolina) two weeks prior to onset of symptoms. The patient was observed without intervention and at four-week follow-up his symptoms had resolved, as did the abnormalities identified with MMI. Best-corrected Snellen visual acuity

* Corresponding author. Department of Ophthalmology, California Pacific Medical Center, West Coast Retina Group, San Francisco, USA.
E-mail address: calectng@gmail.com (C.C. Ng).

https://doi.org/10.1016/j.ajoc.2020.100845
Received 20 June 2020; Received in revised form 19 July 2020; Accepted 26 July 2020
Available online 3 August 2020
2451-9936/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
improved to 20/16-1 in the right eye at this last visit.

3. Discussion

We describe a young, previously healthy man who developed photopsias, paracentral scotomata, and dyschromatopsia in the right eye two weeks following influenza vaccination. Clinical features and findings on MMI were consistent with MEWDS. The subject’s symptoms and ophthalmologic findings resolved four weeks following presentation without intervention.

In 1984, Jampol and colleagues described a new chorioretinal disorder name Multiple Evanescent White Dot Syndrome (MEWDS). While there have been no known racial or hereditary predilections, the disease is most commonly diagnosed in young to middle aged women. As many as 30% of affected patients report a viral prodrome. MEWDS is almost always a unilateral disease, and common symptoms include photopsias, dyschromatopsia, or paracentral scotomata. The disorder is thought to have a benign prognosis with spontaneous resolution after two to three months.

To the best of our knowledge, there have been eight published case of MEWDS following various vaccinations, including rabies, human papilloma virus, hepatitis A, hepatitis B, meningococcal, Yellow fever, and influenza. The demographics and clinical course of all published cases. Including the current, are summarized in Table 1. Our case is the first to employ MMI, and revealed findings typical for MEWDS. Collectively, patients with post-vaccine MEWDS tended to be healthy (77.8%), young to middle age (median 33 years; mean 31.7 years; range 16–53 years) women (66.7%). Racial classification was 44.4% Caucasian, 22.2% Asian, and 33.3% undisclosed. Symptoms manifested on average 13.3 days (median: 14; range: 1-30) after immunization. Mean presenting Snellen visual acuity was of 20/38 (median: 20/25-2, range: 20/16 to 20/200). Patients most commonly described photophobia (88.9%), followed by central or paracentral scotomata (44.4%) and dyschromatopsia (33.3%). Seven cases (77.8%) of post-vaccine MEWDS displayed spontaneous resolution back to baseline Snellen visual acuity over an average of 6.9 weeks (median: 6 weeks; range: 4–12 weeks). The patient with MEWDS following rabies vaccination refused oral corticosteroids, but agreed to receive peri-ocular corticosteroid as part of the treatment protocol. Ogino and colleagues described a case of MEWDS following human papilloma virus vaccine that appeared to have resolved without treatment in two months. Subsequently, the patient noted progressive peripheral vision loss over two years. Repeat imaging revealed mid-peripheral vascular leakage on fluorescein angiography. Due to an allergy to methylprednisolone, she was treated with high dose betamethasone and anti-histamines, leading to drastic reduction in leakage on FA. Unfortunately, the leakage recurred as patient was weaned off the corticosteroid. Given the atypical symptoms and examination findings, the authors discussed the possibility of a different concurrent disease entity, such as acute zonal occult outer retinopathy. Visual acuity at last vision in affected eyes had mean of 20/18.5, with median of 20/20 and range of 20/16 to 20/20.

The exact pathogenesis of MEWDS is yet to be fully elucidated. Most recent hypotheses suggest an immune-mediated mechanism occurring at either the outer retina, the choriocapillaris/inner choroid, or both in genetically predisposed individuals, and the occurrence of MEWDS following vaccination would tend to support such theories. Specifically, vaccines have been suggested to trigger an inflammatory response resulting in uveitis by means of molecular mimicry, or direct antigen-mediated cellular/humoral immune response, adjuvant-mediated inflammation. As many as 160 million doses of influenza vaccine were administered in the United States for the 2019–2020 season, and billions more have been given since the first report of vaccine-associated MEWDS in 1996. It remains possible, therefore, that the occurrence of MEWDS following immunization is coincidental. However, given the generally mild and self-resolving nature of MEWDS, it could also be that post-vaccination cases of MEWDS tend to go unrecognized and unreported. The benefits of continuing to follow established vaccination guidelines far outweigh the risks of uveitis for the vast majority of patients.

Fig. 1. Imaging on presentation: A – Color fundus photo, B – Spectral Domain-Optical coherence tomography, C – Early Fluorescein angiography, D – Late Indocyanine green angiography, E – Fundus Autofluorescence. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
| Study                        | Age | Race    | Gender | Vaccine Type                          | Time from Vaccination (days) | Laterality | Symptoms                          | Comorbidities                                                                 | Presenting VA in affected eye (Snellen) | Vision at Last Visit in Affected Eye | Intervention                      | Time until Resolution (weeks) |
|-----------------------------|-----|---------|--------|---------------------------------------|-------------------------------|------------|----------------------------------|--------------------------------------------------------------------------------|------------------------------------------|-------------------------------------|-----------------------------------|-------------------------------|
| Ng et al., 2020             | 33  | Caucasian | M     | Influenza (Flucelvax Quadrivalent® Seqirus) Rabies | 14                            | Right      | Paracentral scotomata, Photopsias, Grey haze | None                                                                                    | 20/20 + 2                              | 20/16                              | None                              | 4                             |
| Yang et al., 2018           | 33  | Chinese  | F     | Rabies                                | 14                            | Left       | Large paracentral scotoma, Photopsias    | None                                                                                   | 20/20                                   | 20/20                              | Retrobulbar Triamcinolone Acetonide 40 mg | Partially resolved at 8 weeks       |
| Abou-Samra et al., 2018     | 27  | Undisclosed | F     | Influenza                             | 14                            | Right      | Central Photopsias                    | Stevens-Johnson Syndrome, Wolff-Parkinson-White Syndrome, vesicourethral reflux, mild chronic kidney disease, endometriosis, fibroadenomas, depression with anxiety. | 20/25-2                                 | undisclosed                        | None                              | 8                             |
| Ogino et al., 2014          | 16  | Japanese | F     | Human Papilloma Virus (Cervarix®, Glaxo Smith Kline) | 14                            | Left       | Throat pain, Headache, Photopsias, peripheral vision loss | None                                                                                   | 20/16                                   | 20/16                              | None                              | Retinal lesions resolved at two months; worsening peripheral vision loss for 2 years | 4                             |
| Goyal et al., 2013          | 53  | Caucasian | M     | Influenza                             | 10                            | Right      | Purple haze                          | Hepatitis B and C infection, Polysubstance abuse                                    | 20/25-2                                 | 20/20                              | None                              | 8                             |
| Cohen, 2008                 | 17  | Undisclosed | F     | Human Papilloma Virus and meningococcal hepatitis A and Yellow fever | 30                            | Left       | Photopsias, central and paracentral scotomata | None                                                                                   | 20/200                                  | 20/20                              | None                              | 8                             |
| Stangos et al., 2006        | 50  | Caucasian | F     | Hepatitis A                           | 10                            | Left       | Photopsias, paracentral scotomata       | None                                                                                   | 20/40                                   | 20/20                              | None                              | 6                             |
| Fine et al., 2001           | 33  | Caucasian | M     | Hepatitis A                           | 13                            | Left       | Photopsias, Grey haze                 | None                                                                                   | 20/25-2                                 | 20/20                              | None                              | 6                             |
| Baglivo et al., 1996        | 23  | Undisclosed | F     | Hepatitis B booster                   | 1                             | Left       | Left Blurred vision, bilateral photopsias | None                                                                                   | 20/200                                  | Undisclosed                        | "recovery of vision"               | 12                            |
| n = 9                       |     |          |       |                                       |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| Mean: 31.7                  |     | Median: 13.3 |      |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| Median: 14                  |     | OD:OS ratio 1:2 |    |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| Caucasion: 44.4%            |     | Undisclosed: 33.3% |  |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| Median: 14                  |     | OD:OS ratio 1:2 |    |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| Mean: 20/200                |     | Median: 20/ 18.5 |  |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| Mean: 20/25-2               |     | Range: 20/16 - 20/200 | |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| 77.8% None                  |     | Mean: 6.9 |  |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
| Range: 4 - 12               |     | Range: 20/16 - 20/20 | |                                      |                               |            |                                   |                                                                                       |                                        |                                     |                                   |                               |
4. Conclusion

We present the first reported case of MMI of vaccination-associated MEWDS. Comparison with eight previously reported cases of MEWDS following immunization revealed that subjects tended to be healthy, young to middle age women with a median time to onset of two weeks. Vision tended to recover spontaneously over one to three months.

Patient consent

The patient consented to publication of the case in writing.

Funding

San Francisco Retina Foundation

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Declaration of competing interest

None of the authors have any financial disclosures.

Acknowledgments

None.

References

1. Renage M, Fraunfelder FW. Vaccine-associated uveitis. Mo Med. 2016 Jan;113(1):48.
2. Cunningham Jr ET, Moorthy RS, Fraunfelder FW, Zierhut M. Vaccine-Associated Uveitis. Ocular immunology and inflammation. 2019 June 27;27(4):517-520.
3. Cunningham Jr ET, Moorthy RS. Vaccine-associated posterior uveitis. Retina. 2020 April;40(4):595-598.
4. Goyal S, Nazarian SM, Thayi DR, Hammond F, Petrovic V. Multiple evanescent white dot syndrome following recent influenza vaccination. Can J Ophthalmol. 2013 Oct 1;48(5):e115-e116.
5. Abou-Samra A, Tarabishy AB. Multiple evanescent white dot syndrome following intradermal influenza vaccination. Ocul Immunol Inflamm. 2019 May 19;27(4):528-530.
6. Stangos A, Zaninetti M, Petropoulos I, Bagliro E, Pourmaras C. Multiple evanescent white dot syndrome following simultaneous hepatitis-A and yellow fever vaccination. Ocul Immunol Inflamm. 2006 Jan 1;14(5):301-304.
7. Yang JS, Chen CL, Hu YZ, Zeng R. Multiple evanescent white dot syndrome following rabies vaccination: a case report. BMC Ophthalmol. 2018 Dec 1;18(1):312.
8. Cohen SM. Multiple evanescent white dot syndrome after vaccination for human papilloma virus and meningococcus. J Pediatr Ophthalmol Strabismus. 2010 May 1;48:11-43. https://doi.org/10.3928/01913913-20090616-01.
9. Ogino K, Kishi S, Yoshimura N. Multiple evanescent white dot syndrome after human papillomavirus vaccination. Case Rep. Ophthalmol. 2014;5(1):38-43.
10. Fine I, Fine A, Cunningham ET. Multiple evanescent white dot syndrome following hepatitis A vaccination. Arch Ophthalmol. 2001 Dec 1;119(12):1856-1858.
11. Bagliro E, Safran AB, Borruat FX. Multiple evanescent white dot syndrome after hepatitis B vaccine. Am. J. Ophthalmol. 1996 Sep 1;122(3):431-432.
12. Jampol LM, Sieving PA, Pugh D, Fishman GA, Gilbert H. Multiple evanescent white dot syndrome: I. Clinical findings. Arch Ophthalmol. 1984 May 1;102(5):671-674.
13. Marsiglia M, Gallego-Pinazo R, Cunha de Souza E, et al. Expanded clinical spectrum of multiple evanescent white dot syndrome with multimodal imaging. Retina. 2016; 36(1):64-74.
14. Jampol LM, Becker KG. White spot syndromes of the retina: a hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. Am. J. Ophthalmol. 2003 Mar 1;135(3):376-379.
15. Marsiglia M, Gallego-Pinazo R, De Souza EC, et al. Expanded clinical spectrum of multiple evanescent white dot syndrome with multimodal imaging. Retina. 2016 Jan 1;36(1):64-74.
16. Lages V, Mantovani A, Papadia M, Herborg CP. MEWDS is a true primary choriocapillaritis and basic mechanisms do not seem to differ from other choriocapillaritis entities. Journal of Current Ophthalmology. 2018 Dec;30(4):281.
17. Fiore T, Iaccheri B, Cerquaglia A, et al. Outer retinal and choroidal evaluation in multiple evanescent white dot syndrome (MEWDS): an enhanced depth imaging optical coherence tomography study. Ocul Immunol Inflamm. 2018 Apr 3;26(3):428-434.
18. Aoyagi R, Hayashi T, Masai A, et al. Subfoveal choroidal thickness in multiple evanescent white dot syndrome. Clin Exp Optom. 2012 Mar;95(2):212-217.
19. [Internet]. Key Facts about Seasonal Flu Vaccine. 2020 [cited 2020Jun28]. Available from: https://www.cdc.gov/flu/prevent/keyfacts.htm.